Safety of Selegiline (Deprenyl) in the Treatment of Parkinson’s Disease
@article{Heinonen1998SafetyOS, title={Safety of Selegiline (Deprenyl) in the Treatment of Parkinson’s Disease}, author={E. Heinonen and V. Myllyl{\"a}}, journal={Drug Safety}, year={1998}, volume={19}, pages={11-22} }
Selegiline (deprenyl), a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B) is widely used in the treatment of Parkinson’s disease. As the first MAO-B inhibitor approved for the treatment of Parkinson’s disease, concerns were raised about the safety of the drug based on the adverse effect profiles of older, nonselective MAO inhibitors. Unlike the nonselective MAO inhibitors, selegiline does not significantly potentiate tyramine-induced hypertension (the ‘cheese effect’) at… CONTINUE READING
Tables and Topics from this paper
Tables
72 Citations
Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease
- Medicine
- Journal of Neurology
- 2001
- 11
Selegiline: A Reappraisal of Its Role in Parkinson Disease
- Psychology, Medicine
- Clinical neuropharmacology
- 2012
- 31
- Highly Influenced
Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson’s disease
- Medicine
- Patient preference and adherence
- 2011
- 27
- PDF
Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson’s Disease
- Medicine
- CNS Drugs
- 2015
- 53
- PDF
Monamine Oxidase Inhibitors: Current and Emerging Agents for Parkinson Disease
- Medicine
- Clinical neuropharmacology
- 2007
- 60
Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson’s Disease
- Medicine
- Clinical pharmacokinetics
- 2002
- 261
Selegiline orally disintegrating tablets for the treatment of Parkinson’s disease
- Medicine
- Expert review of neurotherapeutics
- 2005
- 17
Droxidopa for the treatment of neurogenic orthostatic hypotension and other symptoms of neurodegenerative disorders
- Medicine
- 2014
- 4
Long-Term Selegiline Monotherapy for the Treatment of Early Parkinson Disease
- Medicine
- Clinical neuropharmacology
- 2019
- PDF
References
SHOWING 1-10 OF 102 REFERENCES
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
- Medicine
- Science
- 1989
- 594
- Highly Influential
Lack of adverse interactions between concomitantly administered selegiline and citalopram.
- Psychology, Medicine
- Clinical neuropharmacology
- 1997
- 53
Fluoxetine and selegiline--lack of significant interaction.
- Medicine
- The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
- 1994
- 38
- PDF
Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease
- Medicine
- Neurology
- 1997
- 177
A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor.
- Psychology, Medicine
- Archives of general psychiatry
- 1989
- 161
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s disease
- Medicine
- 1997
- 34
- PDF
Selegiline in the early and late phases of Parkinson's disease.
- Medicine
- Journal of neural transmission. Supplementum
- 1987
- 28